September 2010 - SeneXta will be present at Biopharm 2010 in Boston
July 2010 - SeneXta Announces The Successful Completion of Phase I study with SNX-001
April 2010 - SeneXta to present at the Swiss Equity biotech day, April 13, 2010 -
Zurich
March 2010 - SeneXta was featured as "Emerging Company" on BioCentury March 1, 2010
January 2010 - SeneXta to present at the Biotech Showcase 2010 conference in San Francisco on January 12
December 2009 - SeneXta Announces Human Dosing with SNX-001 In Phase I Study
October 2009 - SeneXta to present at the 2009 BIOCOM Investor Conference in San Diego on
October 27 www.biocom.org
September 2009- SeneXta to present at Swiss-Scandinavian Bio Seminar in Zurich on October 1st
July 2009 - SeneXta Therapeutics SA announces FDA approval of Investigational New
May 2009 - BioCentury select SENEXTA to present at Bioequity Europe 2009 as New Wave Company
April 2009 - CEO Enrico Braglia will present SeneXta at Lugano Communication Forum
March 2009 - Senexta successfully completed new IND Toxicology Package
January 2009 - SeneXta signs Worldwide Exclusive License Agreement with University of Texas at El Paso
November 2008
- SeneXta starts preclinical development on SNX-001
- Prof. Fariello join SeneXta team as Clinical Advisor
- SeneXta completed cGMP development of SNX-001
- SeneXta signs letter of intent with University of Texas El Paso
- SeneXta Therapeutics SA is incorporated in Switzerland